Francesca Palandri

9.3k total citations · 1 hit paper
180 papers, 3.2k citations indexed

About

Francesca Palandri is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Francesca Palandri has authored 180 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Genetics, 135 papers in Hematology and 62 papers in Rheumatology. Recurrent topics in Francesca Palandri's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (112 papers), Chronic Myeloid Leukemia Treatments (88 papers) and Eosinophilic Disorders and Syndromes (62 papers). Francesca Palandri is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (112 papers), Chronic Myeloid Leukemia Treatments (88 papers) and Eosinophilic Disorders and Syndromes (62 papers). Francesca Palandri collaborates with scholars based in Italy, United States and United Kingdom. Francesca Palandri's co-authors include Michele Baccarani, Nicola Vianelli, Fausto Castagnetti, Nicola Polverelli, Lucia Catani, Giovanni Martinelli, Giuliana Alimena, Gianantonio Rosti, Gabriele Gugliotta and Simona Soverini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Francesca Palandri

164 papers receiving 3.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

2007 540 citations Francesca Palandri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesca Palandri Italy	30	2.4k	2.2k	1.2k	653	293	180	3.2k
Elisabetta Abruzzese Italy	27	2.5k 1.1×	1.8k 0.8×	1.1k 0.9×	399 0.6×	538 1.8×	150	3.2k
Zbigniew Rudzki Australia	21	2.7k 1.1×	2.2k 1.0×	1.5k 1.3×	709 1.1×	586 2.0×	101	3.8k
François Delhommeau France	26	3.0k 1.3×	3.7k 1.7×	1.4k 1.1×	2.7k 4.1×	657 2.2×	81	5.2k
S Swanton United Kingdom	8	2.2k 0.9×	3.1k 1.4×	1.3k 1.1×	1.9k 2.9×	594 2.0×	11	3.7k
Éric Lippert France	23	1.3k 0.5×	1.4k 0.7×	603 0.5×	968 1.5×	278 0.9×	102	2.2k
Nasios Fourouclas United Kingdom	7	2.1k 0.9×	3.1k 1.4×	1.3k 1.1×	1.9k 2.9×	601 2.1×	8	3.6k
Natasha Joan Curtin United Kingdom	5	2.0k 0.8×	3.0k 1.4×	1.3k 1.0×	1.8k 2.7×	578 2.0×	6	3.5k
Clare East United Kingdom	7	2.7k 1.1×	4.2k 1.9×	1.8k 1.5×	2.6k 4.0×	610 2.1×	14	4.7k
Ron Paquette United States	12	1.8k 0.7×	1.2k 0.5×	625 0.5×	540 0.8×	390 1.3×	23	2.2k
Andrzej Hellmann Poland	23	1.5k 0.6×	1.8k 0.8×	320 0.3×	548 0.8×	589 2.0×	58	3.1k

Countries citing papers authored by Francesca Palandri

Since Specialization

Citations

This map shows the geographic impact of Francesca Palandri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Palandri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Palandri more than expected).

Fields of papers citing papers by Francesca Palandri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Palandri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Palandri. The network helps show where Francesca Palandri may publish in the future.

Co-authorship network of co-authors of Francesca Palandri

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Palandri. A scholar is included among the top collaborators of Francesca Palandri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Palandri. Francesca Palandri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Biagioli, Valentina, Antonella Barone, Alessandra Iurlo, et al.. (2025). Validity and Reliability of the Self‐Care in MyeloProliferative Neoplasms Inventory (SC‐MPNI). European Journal of Cancer Care. 2025(1).

Breccia, Massimo, Francesca Palandri, Francesco Passamonti, et al.. (2024). The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries. British Journal of Haematology. 206(1). 172–179. 1 indexed citations

Kuykendall, Andrew, Somedeb Ball, Barbara Mora, et al.. (2024). Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO Precision Oncology. 8(8). e2300593–e2300593. 3 indexed citations

Vachhani, Pankit, et al.. (2024). Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.. Journal of Clinical Oncology. 42(16_suppl). 6578–6578.

Watts, Justin M., Alessandro M. Vannucchi, Anthony M. Hunter, et al.. (2024). Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.. Journal of Clinical Oncology. 42(16_suppl). 6576–6576. 1 indexed citations

Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 11(10). e729–e740. 11 indexed citations

Pemmaraju, Naveen, Tim C. P. Somervaille, Francesca Palandri, et al.. (2024). Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. PubMed. 2(1). 100056–100056. 1 indexed citations

Breccia, Massimo, Francesca Palandri, Nicola Polverelli, et al.. (2024). Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives. Frontiers in Oncology. 14. 1382872–1382872. 1 indexed citations

Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.. Journal of Clinical Oncology. 41(16_suppl). 7018–7018. 1 indexed citations

10.

Palandri, Francesca, et al.. (2023). Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers. 15(10). 2859–2859. 7 indexed citations

11.

Breccia, Massimo, Francesca Palandri, Paola Guglielmelli, et al.. (2022). Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology. 29(7). 4970–4980. 4 indexed citations

12.

Forte, Dorian, Martina Barone, Cristina Morsiani, et al.. (2021). Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. Journal of Experimental & Clinical Cancer Research. 40(1). 49–49. 14 indexed citations

13.

Catani, Lucia, Michèle Cavo, & Francesca Palandri. (2021). The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters. Cells. 10(9). 2316–2316. 9 indexed citations

14.

Forte, Dorian, Martina Barone, Francesca Palandri, & Lucia Catani. (2021). The “Vesicular Intelligence” Strategy of Blood Cancers. Genes. 12(3). 416–416. 12 indexed citations

15.

Barone, Martina, Francesca Ricci, Daria Sollazzo, et al.. (2018). Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. British Journal of Haematology. 185(5). 987–991. 16 indexed citations

16.

Forte, Dorian, Daria Sollazzo, Martina Barone, et al.. (2018). Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34⁺Cells. Mediators of Inflammation. 2018. 1–14. 3 indexed citations

17.

Giraldo, Pilar, Francesca Palandri, Giuseppe A. Palumbo, et al.. (2015). SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY. Haematologica. 100. 265–265. 5 indexed citations

18.

Baccarani, Michele, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, & Gianantonio Rosti. (2014). TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases. 6(1). e2014005–e2014005. 31 indexed citations

19.

Castagnetti, Fausto, Francesca Palandri, Gabriele Gugliotta, et al.. (2009). Thyrosin kinase inhibitors: nilotinib. 2(5). 22–26. 1 indexed citations

20.

Martinelli, Giovanni, Ilaria Iacobucci, Simona Soverini, et al.. (2007). Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.. Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna). 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact